Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.

Drenner, Kevin; Basu, Gargi D; Goodman, Laurie J; Ozols, Audrey A; LoBello, Janine R; Royce, Thomas; Gordon, Michael S; Borazanci, Erkut H; Steinbach, Margaux A; Trent, Jeffrey; Sharma, Sunil

Drenner, Kevin; Basu, Gargi D; Goodman, Laurie J; Ozols, Audrey A; LoBello, Janine R; Royce, Thomas; Gordon, Michael S; Borazanci, Erkut H; Steinbach, Margaux A; Trent, Jeffrey; Sharma, Sunil.

Afiliação

Drenner K; Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA.
Basu GD; Ashion Analytics, LLC, Phoenix, AZ 85004, USA.
Goodman LJ; Ashion Analytics, LLC, Phoenix, AZ 85004, USA.
Ozols AA; Ashion Analytics, LLC, Phoenix, AZ 85004, USA.
LoBello JR; Ashion Analytics, LLC, Phoenix, AZ 85004, USA.
Royce T; Ashion Analytics, LLC, Phoenix, AZ 85004, USA.
Gordon MS; HonorHealth Research Institute, Scottsdale, AZ 85258, USA.
Borazanci EH; HonorHealth Research Institute, Scottsdale, AZ 85258, USA.
Steinbach MA; HonorHealth Research Institute, Scottsdale, AZ 85258, USA.
Trent J; Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA.
Sharma S; Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA.

Oncotarget ; 13: 1174, 2022 Oct 20.

Article em En | MEDLINE | ID: mdl-36289011

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google